Close Icon
Close Icon
Close Icon

The Automated CDMO For Regenerative Medicine

Powered by Mytos' iDEM™ automation technology, Mytos CDMO enables scalable, consistent production at low cost per dose. Site 1 is housed within CGT Catapult's 80,000 sqft site, with plans in place for a series of global sites.

Manufacturing That Can Scale

Avoid long hiring and training delays during scaling, with scalable automated manufacturing

One-Stop-Shop

Between our team and our partners, Mytos handles every part of Manufacturing - from Process & Analytical Development, to Regulatory Support  

Preserve Your Runway

No suite fees, no iDEM device purchases, no hidden costs

Cut Batch Costs

Save up to 50% compared with manual CDMOs

Mytos x catapult CDMO headquarters

iDEM™ Automates All the Unit Operations in Cell Culture

Coating, seeding, feeding, cell imaging, passaging, harvesting
Coating, seeding, feeding, cell lmaging, passaging, harvesting
Automate Without Compromising the Biology

iDEM uses the same 2D T flask format as manual culture, enabling manual protocols to be rapidly ported to closed automation - without affecting the biology

Unparalled Productivity

iDEM reduces labour per batch by up to 10x compared to manual culture - and reduces cleanroom footprint per batch by another 10x

Consistent Quality At Scale

Reliably scale at the quality of your best operator - and avoid expensive operator-related batch failures

Closed & Reliable

Unlike large robotic arm solutions, our iDEM fleet doesn't have a single point of failure - reducing the risk of production delays  

Mytos IDEM machines stacked

The Automated CDMO for Regenerative Medicine

Mytos's CDMO, powered by IDEM, delivers unmatched costs, scale, and efficiency.

Mytos X catapult logo
Mytos x catapult CDMO headquarters
Mytos' innovation paired with CGT Catapult's GMP and Regulatory gives teams anunparalleled path to scale and commercial viability.
Affordability

50% Lower Batch Costs 

 Up to 50% cost reduction in batch prices compared to manual CDMOs.

Extend Runway

Preserve Runway

No suite fees or iDEM purchases required.

Speed

Avoid Delays

Reduce tech transfers and hiring delays with iDEM-powered manufacturing that enables rapid scaling.



“The Mytos iDEM system—together with our bioinformatics and other enabling technologies—allows us to scale out for Phase 3 and ultimately commercialization, making more product at lower cost.”

Kim Raineri

CTO | Aspen Neuroscience



"Mytos offered a unique and practical bridge from manual to automated production, even at an early stage."

Dr. Laura Koivusalo

CEO | Stemsight



"With Mytos, we have the opportunity to seamlessly automate our existing process without having to change the biology."

Dr. Terri Gaskell

CTO | Rinri Therapeutics



"Mytos enables us to increase the output of our existing facilities, without having to delay scaling to build out new capacity."

Neil Johnson

CTO | Novadip

Recent News

Ali and Ignacio posing
Sept 8 2025

Mytos announces 3 new partnerships across cells for bone fractures, deafness & more

Mytos announces new manufacturing collaborations with three innovative biotech companies...

IDEM machines stacked together
Sept 3 2025

Mytos Announces Partnerships with StemSight, Rinri Therapeutics, and Novadip

Mytos’ iDEM technology will power manufacturing of neuronal precursor cells...

Mytos iDEM cell manufacturing system
Jan 8 2025

Mytos Announces Manufacturing Collaboration with Aspen Neuroscience

Aspen will integrate Mytos’ iDEM automated cell technology into its 22,000-square-foot...

Backed by